Clinical trial
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive)…
NCT04583735 · Amgen, Industry · Completed
Key facts
| NCT number | NCT04583735 |
|---|---|
| Title | A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease |
| Official title | A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease |
| Intervention type | Biological, Drug |
| Interventions | TEPEZZA, Placebo |
| Enrollment | 62 |
| Start date | Sep 2, 2021 |
| Primary completion | Mar 17, 2023 |
| Completion | Oct 12, 2023 |
| First posted | Oct 12, 2020 |
| Last update posted | Jul 1, 2024 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: